Clinical Trials Logo

Dengue clinical trials

View clinical trials related to Dengue.

Filter by:

NCT ID: NCT00473135 Completed - Dengue Clinical Trials

Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus Vaccine

Start date: May 2007
Phase: Phase 1
Study type: Interventional

Dengue fever, caused by dengue viruses, is a major health problem in tropical and subtropical regions of the world. The purpose of this study is to evaluate the safety of and immune response to a 2-dose regimen of a new monovalent dengue virus vaccine. This study will test the dengue virus vaccine DEN1delta30 in healthy adults.

NCT ID: NCT00468858 Completed - Dengue Fever Clinical Trials

A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children

Start date: July 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of two different formulations of an investigational dengue vaccine (T-DEN) against a placebo vaccine when two doses are given six months apart to adults and children.

NCT ID: NCT00458120 Completed - Clinical trials for Dengue Hemorrhagic Fever

Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus

Start date: March 2007
Phase: Phase 1
Study type: Interventional

Dengue fever, which is caused by dengue viruses, is a major health problem in subtropical regions of the world. There are four different forms (serotypes) of dengue virus that can cause dengue fever. The purpose of this study is to determine the safety and immune response to a vaccine containing a particular dengue serotype when an individual has been previously vaccinated with a different dengue serotype.

NCT ID: NCT00384670 Completed - Dengue Fever Clinical Trials

A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children

Start date: August 2003
Phase: Phase 1/Phase 2
Study type: Interventional

To assess the safety, reactogenicity and immunogenicity of two doses of the dengue vaccine in Flavi-virus antibody-naive children between 6 and 9 years of age.

NCT ID: NCT00375726 Completed - Dengue Clinical Trials

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults

Start date: October 2006
Phase: Phase 1
Study type: Interventional

Dengue fever, caused by dengue viruses, is a major health problem in the tropical and subtropical regions of the world. The purpose of this study is to test the safety of and immune response to a new dengue virus vaccine in healthy adults.

NCT ID: NCT00370682 Completed - Dengue Clinical Trials

A Phase II Trial of a Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy Adults in Thailand

Start date: April 2007
Phase: Phase 2
Study type: Interventional

This descriptive study will evaluate the safety and immunogenicity of different formulations of the WRAIR dengue vaccine compared to a placebo.

NCT ID: NCT00350337 Completed - Dengue Clinical Trials

Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults

Start date: April 5, 2006
Phase: Phase 2
Study type: Interventional

This descriptive study will evaluate the safety and immunogenicity of 3 different formulations of the WRAIR dengue vaccine compared to a placebo.

NCT ID: NCT00322946 Completed - Dengue Clinical Trials

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-4995) in Healthy Adults

Start date: January 2007
Phase: Phase 1
Study type: Interventional

Dengue fever, which is caused by dengue viruses, is a major health problem in tropical and subtropical regions of the world. The purpose of this study is to evaluate the safety and immune response to the dengue vaccine DEN4delta30-4995 in healthy adults.

NCT ID: NCT00322049 Completed - Dengue Clinical Trials

A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants

Start date: February 2004
Phase: Phase 1/Phase 2
Study type: Interventional

The main target populations for the tetravalent live attenuated dengue virus vaccine are indigenous populations, especially infants less than 2 years old, residing in areas of the world endemic for dengue and at risk of developing dengue hemorrhagic fever (DHF). The presence of maternal dengue antibody during the first year of life makes it unlikely that a vaccine given during that time will have long-term efficacy, as the vaccine virus would likely be neutralized prior to necessary replication. Children older than 18 months may have preexisting flavivirus antibody. Therefore, vaccination of infants living in Thailand early in the second year of life (between the ages of 12 and 18 months) seems most beneficial. The aim of this trial is to evaluate the safety and immunogenicity of a two-dose schedule of a tetravalent live attenuated dengue vaccine in flavivirus antibody naïve infants beginning at 12-15 months of age. - To assess the kinetics of dengue neutralizing antibodies to each dengue virus serotype one and four years following dose 2 of dengue/control vaccination in the setting of potential wild-type dengue virus exposure. - To assess the immunogenicity, the safety and reactogenicity of a booster dose of dengue vaccine administered at Year 3 following primary vaccination.

NCT ID: NCT00290147 Completed - Dengue Clinical Trials

Safety Study of a Dengue Virus DNA Vaccine

Start date: January 2006
Phase: Phase 1
Study type: Interventional

The purpose of this study is to exame the safety of a DNA vaccine against dengue-1.